Showing results (121-130 of 180) with videos related to

Sort By:
Pageof 18
European Journal of Medicinal Chemistry|August 3, 2025
Biomacromolecule-mediated targeted protein degradation: an emerging strategy for cancer therapyMeiyang Xi, Fengxia Zhang, Jingjing Zhu, et al.
International Immunopharmacology|June 30, 2024
Diosgenin attenuates metabolic-associated fatty liver disease through the hepatic NLRP3 inflammasome-dependent signaling pathwayWenfei Yu, Guoliang Yin, Suwen Chen, et al.
European Journal of Medicinal Chemistry|July 28, 2024
Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloadsMeiyang Xi, Jingjing Zhu, Fengxia Zhang, et al.
Toxicology and Applied Pharmacology|December 31, 2020
Diosgenin alleviates hypercholesterolemia via SRB1/CES-1/CYP7A1/FXR pathway in high-fat diet-fed ratsLu Yu, Haifei Lu, Xiufen Yang, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|September 23, 2021
The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A ReviewFengcui Sun, Xiufen Yang, Chaoqun Ma, et al.
European Journal of Pharmacology|June 12, 2024
Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic SIRT1/PGC-1α pathwayDecheng Meng, Guoliang Yin, Suwen Chen, et al.
Chemico-Biological Interactions|November 13, 2024
Diosgenin attenuates nonalcoholic fatty liver disease through mTOR-mediated inhibition of lipid accumulation and inflammationGuoliang Yin, Hongyi Liang, Yiran Cheng, et al.
Pageof 18